← Leaderboards
Charles Houston Jones
Abcombi Biosciences, Inc.
$3,162,435
Attributed
$3,162,435
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $940.5K · FY2016–22$1M$750K$500K$250K$0
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$3,162,435 · 3
By mechanism
R44$2,512,535 · 1
R41$349,900 · 1
R43$300,000 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Success”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$277,058,716
- Lawrence Corey · Fred Hutchinson Cancer Center$274,406,165
- Barton F Haynes · Duke University$260,353,372
Research focus
SuccessVirulenceFormulationVaccinesDesignMortalityIncidenceBaseToxic EffectSafetyImmunologicsCountryAnimalsImmunoglobulin MAdultImmunoglobulin GBacterial MeningitisAntibody Titer MeasurementBacteremiaChemistryGlycoconjugatesAntigensChildAntibodies
Grant awards (6)
DEVELOPMENT OF A LIPOSOMAL PNEUMOCOCCAL VACCINE FOR CLINICAL READINESS$856,101
R44 · FY2022 · AI · contact PI
DEVELOPMENT OF A LIPOSOMAL PNEUMOCOCCAL VACCINE FOR CLINICAL READINESS$940,483
R44 · FY2021 · AI · contact PI
DEVELOPMENT OF A LIPOSOMAL PNEUMOCOCCAL VACCINE FOR CLINICAL READINESS$715,951
R44 · FY2020 · AI · contact PI
Lead Candidate Finalization and a Comprehensive Biological Assessment of a New Class of Pneumococcal Vaccines$300,000
R43 · FY2018 · AI · contact PI
Therapy for drug resistant influenza strains by nucleic acid targeting of respiratory airways$49,900
R41 · FY2017 · AI · contact PI
Therapy for drug resistant influenza strains by nucleic acid targeting of respiratory airways$300,000
R41 · FY2016 · AI · contact PI